SlideShare a Scribd company logo
The New England
      Journal of Medicine
    Dabigatran versus Warfarin in Patients
            with Atrial Fibrillation

                   FEDERICO FAILACH N. M.D.
              RESIDENTE II AÑO MEDICINA INTERNA
                    UNIVERSIDAD DEL SINÚ

.
METODO
• The Randomized Evaluation of Long-Term Anti-
  coagulation Therapy (RE-LY)

• Patients were recruited from 951 clinical centers
  in 44 countries.

• Blinded fashion, fixed doses of Dabigatran 110
  mg or 150 mg twice daily

• Unblended fashion, adjusted-dose warfarin.

© your company name. All rights reserved.     Title of your presentation
CRITERIOS DE INCLUSIÓN Y
           EXCLUSIÓN.
•    previous stroke or transient      •  Severe heart-valve disorder
    ischemic attack.                   •  Stroke with- in 14 days or
•    Left ventricular ejection           severe stroke within 6 months
    fraction of less than 40%            before screening
•   New York Heart Association         • Condition that increased the
    class II or higher heart-failure     risk of hemorrhage
    symptoms within 6 months           • Creatinine clearance of less
    before screening                     than 30 ml per minute
•   Age of at least 75 years or an     • Active liver disease, and
    age of 65 to 74 years                pregnancy.
•    Diabetes mellitus,
    hypertension, or coronary ar
    tery disease
TABLA 1.




© your company name. All rights reserved.      Title of your presentation
Strategy
Film Title




© your company name. All rights reserved.   Title of your presentation
Strategy




                        Make your point.
                         Keep it simple.


© your company name. All rights reserved.   Title of your presentation
Your Decision
Which will be your
primary focus?
© your company name. All rights reserved.   Title of your presentation

More Related Content

Viewers also liked

Insuficiencia cardíaca avanzada
Insuficiencia cardíaca avanzadaInsuficiencia cardíaca avanzada
Insuficiencia cardíaca avanzada
Edgardo Alania Torres
 
Anticoagulantes orales
Anticoagulantes oralesAnticoagulantes orales
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
Sociedad Española de Cardiología
 
Perspectiva del cardiólogo intervencionista
Perspectiva del cardiólogo intervencionistaPerspectiva del cardiólogo intervencionista
Perspectiva del cardiólogo intervencionista
Sociedad Española de Cardiología
 
Hipertensión endócrina 2
Hipertensión endócrina 2Hipertensión endócrina 2
Hipertensión endócrina 2
Mocte Salaiza
 
Lo mejor en Arritmias
Lo mejor en ArritmiasLo mejor en Arritmias
Lo mejor en Arritmias
Sociedad Española de Cardiología
 
Lo mejor en Riesgo CV
Lo mejor en Riesgo CVLo mejor en Riesgo CV
Lo mejor en Riesgo CV
Sociedad Española de Cardiología
 
La más reciente incorporación: Edoxaban y el estudio ENGAGE.
La más reciente incorporación: Edoxaban y el estudio ENGAGE.La más reciente incorporación: Edoxaban y el estudio ENGAGE.
La más reciente incorporación: Edoxaban y el estudio ENGAGE.
Sociedad Española de Cardiología
 
Paciente con angina de esfuerzo y revascularización incompleta
Paciente con angina de esfuerzo y revascularización incompletaPaciente con angina de esfuerzo y revascularización incompleta
Paciente con angina de esfuerzo y revascularización incompleta
Sociedad Española de Cardiología
 
DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPYDUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
drskd6
 
Anticoagulación en pacientes sometidos a cardioversión y ablación
Anticoagulación en pacientes sometidos a cardioversión y ablaciónAnticoagulación en pacientes sometidos a cardioversión y ablación
Anticoagulación en pacientes sometidos a cardioversión y ablación
Sociedad Española de Cardiología
 
Anticoagulación 3.0 con idarucizumab
Anticoagulación 3.0 con idarucizumabAnticoagulación 3.0 con idarucizumab
Anticoagulación 3.0 con idarucizumab
Sociedad Española de Cardiología
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
Virrey Solis IPS
 
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
Sociedad Española de Cardiología
 
Lo mejor en Insuficiencia Cardiaca y Cardiología Clínica
Lo mejor en Insuficiencia Cardiaca y Cardiología ClínicaLo mejor en Insuficiencia Cardiaca y Cardiología Clínica
Lo mejor en Insuficiencia Cardiaca y Cardiología Clínica
Sociedad Española de Cardiología
 
Perspectiva del cardiólogo clínico
Perspectiva del cardiólogo clínicoPerspectiva del cardiólogo clínico
Perspectiva del cardiólogo clínico
Sociedad Española de Cardiología
 
Paciente con cardiopatía isquémica y diabético
Paciente con cardiopatía isquémica y diabéticoPaciente con cardiopatía isquémica y diabético
Paciente con cardiopatía isquémica y diabético
Sociedad Española de Cardiología
 
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
José Antonio García Erce
 
Electrocardiografía. El ABC en Gráficas
Electrocardiografía.  El ABC en GráficasElectrocardiografía.  El ABC en Gráficas
Electrocardiografía. El ABC en Gráficas
Rigoberto José Meléndez Cuauro
 
Ecg flash cards_new_complete
Ecg flash cards_new_completeEcg flash cards_new_complete
Ecg flash cards_new_complete
Mario Mancini
 

Viewers also liked (20)

Insuficiencia cardíaca avanzada
Insuficiencia cardíaca avanzadaInsuficiencia cardíaca avanzada
Insuficiencia cardíaca avanzada
 
Anticoagulantes orales
Anticoagulantes oralesAnticoagulantes orales
Anticoagulantes orales
 
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria p...
 
Perspectiva del cardiólogo intervencionista
Perspectiva del cardiólogo intervencionistaPerspectiva del cardiólogo intervencionista
Perspectiva del cardiólogo intervencionista
 
Hipertensión endócrina 2
Hipertensión endócrina 2Hipertensión endócrina 2
Hipertensión endócrina 2
 
Lo mejor en Arritmias
Lo mejor en ArritmiasLo mejor en Arritmias
Lo mejor en Arritmias
 
Lo mejor en Riesgo CV
Lo mejor en Riesgo CVLo mejor en Riesgo CV
Lo mejor en Riesgo CV
 
La más reciente incorporación: Edoxaban y el estudio ENGAGE.
La más reciente incorporación: Edoxaban y el estudio ENGAGE.La más reciente incorporación: Edoxaban y el estudio ENGAGE.
La más reciente incorporación: Edoxaban y el estudio ENGAGE.
 
Paciente con angina de esfuerzo y revascularización incompleta
Paciente con angina de esfuerzo y revascularización incompletaPaciente con angina de esfuerzo y revascularización incompleta
Paciente con angina de esfuerzo y revascularización incompleta
 
DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPYDUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
 
Anticoagulación en pacientes sometidos a cardioversión y ablación
Anticoagulación en pacientes sometidos a cardioversión y ablaciónAnticoagulación en pacientes sometidos a cardioversión y ablación
Anticoagulación en pacientes sometidos a cardioversión y ablación
 
Anticoagulación 3.0 con idarucizumab
Anticoagulación 3.0 con idarucizumabAnticoagulación 3.0 con idarucizumab
Anticoagulación 3.0 con idarucizumab
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
Seguimiento de pacientes con FA y SCA tras intervención coronaria percutánea....
 
Lo mejor en Insuficiencia Cardiaca y Cardiología Clínica
Lo mejor en Insuficiencia Cardiaca y Cardiología ClínicaLo mejor en Insuficiencia Cardiaca y Cardiología Clínica
Lo mejor en Insuficiencia Cardiaca y Cardiología Clínica
 
Perspectiva del cardiólogo clínico
Perspectiva del cardiólogo clínicoPerspectiva del cardiólogo clínico
Perspectiva del cardiólogo clínico
 
Paciente con cardiopatía isquémica y diabético
Paciente con cardiopatía isquémica y diabéticoPaciente con cardiopatía isquémica y diabético
Paciente con cardiopatía isquémica y diabético
 
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
GENERALIDADES E INDICACIONES DE LOS NACOS. VISIÓN DEL HEMATÓLOGO. SCARE COLOM...
 
Electrocardiografía. El ABC en Gráficas
Electrocardiografía.  El ABC en GráficasElectrocardiografía.  El ABC en Gráficas
Electrocardiografía. El ABC en Gráficas
 
Ecg flash cards_new_complete
Ecg flash cards_new_completeEcg flash cards_new_complete
Ecg flash cards_new_complete
 

Similar to Re ly

Ppt chapter 29
Ppt chapter 29Ppt chapter 29
Ppt chapter 29
stanbridge
 
Kelly-DOAC_overview_2017_fo.pptx
Kelly-DOAC_overview_2017_fo.pptxKelly-DOAC_overview_2017_fo.pptx
Kelly-DOAC_overview_2017_fo.pptx
AdelSALLAM4
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
stanbridge
 
Older Anticoagulants
Older AnticoagulantsOlder Anticoagulants
Older Anticoagulants
Mohammad Mahfuzul Islam
 
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
marcus evans Network
 
Dr. Ganasani
Dr. GanasaniDr. Ganasani
Apixaban Vs Warfarin In Patients With Atrial Fibrillation
Apixaban Vs Warfarin In Patients With Atrial FibrillationApixaban Vs Warfarin In Patients With Atrial Fibrillation
Apixaban Vs Warfarin In Patients With Atrial Fibrillation
smithl1819
 
Dapt vs triple therapy, jacc
Dapt vs triple therapy, jaccDapt vs triple therapy, jacc
Dapt vs triple therapy, jacc
Khushboo Gandhi
 
Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)
Sandeepkumar Balabbigari, PharmD, RPh
 
Cenegenics Heart Disease Brochure
Cenegenics Heart Disease BrochureCenegenics Heart Disease Brochure
Cenegenics Heart Disease Brochure
DyriRattlingourd
 
P2 y12 inhibitors during pci for acute coronary syndromes
P2 y12 inhibitors during pci for acute coronary syndromesP2 y12 inhibitors during pci for acute coronary syndromes
P2 y12 inhibitors during pci for acute coronary syndromes
Ahmed Kamel
 
804185 slide
804185 slide804185 slide
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
AbdirisaqJacda1
 
Hypertension
HypertensionHypertension
Hypertension
Oriba Dan Langoya
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44
stanbridge
 

Similar to Re ly (15)

Ppt chapter 29
Ppt chapter 29Ppt chapter 29
Ppt chapter 29
 
Kelly-DOAC_overview_2017_fo.pptx
Kelly-DOAC_overview_2017_fo.pptxKelly-DOAC_overview_2017_fo.pptx
Kelly-DOAC_overview_2017_fo.pptx
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Older Anticoagulants
Older AnticoagulantsOlder Anticoagulants
Older Anticoagulants
 
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
Modern Approaches to Heart Disease Detection - Carl H. Rosner, CardioMag Imag...
 
Dr. Ganasani
Dr. GanasaniDr. Ganasani
Dr. Ganasani
 
Apixaban Vs Warfarin In Patients With Atrial Fibrillation
Apixaban Vs Warfarin In Patients With Atrial FibrillationApixaban Vs Warfarin In Patients With Atrial Fibrillation
Apixaban Vs Warfarin In Patients With Atrial Fibrillation
 
Dapt vs triple therapy, jacc
Dapt vs triple therapy, jaccDapt vs triple therapy, jacc
Dapt vs triple therapy, jacc
 
Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)
 
Cenegenics Heart Disease Brochure
Cenegenics Heart Disease BrochureCenegenics Heart Disease Brochure
Cenegenics Heart Disease Brochure
 
P2 y12 inhibitors during pci for acute coronary syndromes
P2 y12 inhibitors during pci for acute coronary syndromesP2 y12 inhibitors during pci for acute coronary syndromes
P2 y12 inhibitors during pci for acute coronary syndromes
 
804185 slide
804185 slide804185 slide
804185 slide
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44
 

More from Virrey Solis IPS

Hipotiroidismo
HipotiroidismoHipotiroidismo
Hipotiroidismo
Virrey Solis IPS
 
Defensa del proyecto de investigacion
Defensa del proyecto de investigacionDefensa del proyecto de investigacion
Defensa del proyecto de investigacion
Virrey Solis IPS
 
Sepsis universidad de cartagena
Sepsis universidad de cartagenaSepsis universidad de cartagena
Sepsis universidad de cartagena
Virrey Solis IPS
 
Transfusiones masivas
Transfusiones masivasTransfusiones masivas
Transfusiones masivas
Virrey Solis IPS
 
Ecd...
Ecd...Ecd...
Ecd...
Ecd...Ecd...
Fisiologia de la respiracion.
Fisiologia de la respiracion.Fisiologia de la respiracion.
Fisiologia de la respiracion.
Virrey Solis IPS
 
Artritis reumatoidea
Artritis reumatoideaArtritis reumatoidea
Artritis reumatoidea
Virrey Solis IPS
 
Enfoque del paciente reumatologico
Enfoque del paciente reumatologicoEnfoque del paciente reumatologico
Enfoque del paciente reumatologico
Virrey Solis IPS
 
Carbamepenemicos ii
Carbamepenemicos iiCarbamepenemicos ii
Carbamepenemicos ii
Virrey Solis IPS
 
Cancer de ovario
Cancer de ovarioCancer de ovario
Cancer de ovario
Virrey Solis IPS
 
Biologia molecular del ca de pulmon
Biologia molecular del ca de pulmonBiologia molecular del ca de pulmon
Biologia molecular del ca de pulmon
Virrey Solis IPS
 
Oncologia
Oncologia Oncologia
Oncologia
Virrey Solis IPS
 
Sindrome de vena cava superior
Sindrome de vena cava superiorSindrome de vena cava superior
Sindrome de vena cava superior
Virrey Solis IPS
 
Tbc multiresistente
Tbc multiresistenteTbc multiresistente
Tbc multiresistente
Virrey Solis IPS
 
Tbc pulmonar (neumologia)
Tbc pulmonar (neumologia)Tbc pulmonar (neumologia)
Tbc pulmonar (neumologia)
Virrey Solis IPS
 
Epoc
EpocEpoc
Hta y erc desafios
Hta y erc desafiosHta y erc desafios
Hta y erc desafios
Virrey Solis IPS
 
Estudio veteranos
Estudio veteranosEstudio veteranos
Estudio veteranos
Virrey Solis IPS
 
Sesión+cl..[1]
Sesión+cl..[1]Sesión+cl..[1]
Sesión+cl..[1]
Virrey Solis IPS
 

More from Virrey Solis IPS (20)

Hipotiroidismo
HipotiroidismoHipotiroidismo
Hipotiroidismo
 
Defensa del proyecto de investigacion
Defensa del proyecto de investigacionDefensa del proyecto de investigacion
Defensa del proyecto de investigacion
 
Sepsis universidad de cartagena
Sepsis universidad de cartagenaSepsis universidad de cartagena
Sepsis universidad de cartagena
 
Transfusiones masivas
Transfusiones masivasTransfusiones masivas
Transfusiones masivas
 
Ecd...
Ecd...Ecd...
Ecd...
 
Ecd...
Ecd...Ecd...
Ecd...
 
Fisiologia de la respiracion.
Fisiologia de la respiracion.Fisiologia de la respiracion.
Fisiologia de la respiracion.
 
Artritis reumatoidea
Artritis reumatoideaArtritis reumatoidea
Artritis reumatoidea
 
Enfoque del paciente reumatologico
Enfoque del paciente reumatologicoEnfoque del paciente reumatologico
Enfoque del paciente reumatologico
 
Carbamepenemicos ii
Carbamepenemicos iiCarbamepenemicos ii
Carbamepenemicos ii
 
Cancer de ovario
Cancer de ovarioCancer de ovario
Cancer de ovario
 
Biologia molecular del ca de pulmon
Biologia molecular del ca de pulmonBiologia molecular del ca de pulmon
Biologia molecular del ca de pulmon
 
Oncologia
Oncologia Oncologia
Oncologia
 
Sindrome de vena cava superior
Sindrome de vena cava superiorSindrome de vena cava superior
Sindrome de vena cava superior
 
Tbc multiresistente
Tbc multiresistenteTbc multiresistente
Tbc multiresistente
 
Tbc pulmonar (neumologia)
Tbc pulmonar (neumologia)Tbc pulmonar (neumologia)
Tbc pulmonar (neumologia)
 
Epoc
EpocEpoc
Epoc
 
Hta y erc desafios
Hta y erc desafiosHta y erc desafios
Hta y erc desafios
 
Estudio veteranos
Estudio veteranosEstudio veteranos
Estudio veteranos
 
Sesión+cl..[1]
Sesión+cl..[1]Sesión+cl..[1]
Sesión+cl..[1]
 

Recently uploaded

Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"
National Information Standards Organization (NISO)
 
CIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdfCIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdf
blueshagoo1
 
Data Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsxData Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsx
Prof. Dr. K. Adisesha
 
How to Predict Vendor Bill Product in Odoo 17
How to Predict Vendor Bill Product in Odoo 17How to Predict Vendor Bill Product in Odoo 17
How to Predict Vendor Bill Product in Odoo 17
Celine George
 
Haunted Houses by H W Longfellow for class 10
Haunted Houses by H W Longfellow for class 10Haunted Houses by H W Longfellow for class 10
Haunted Houses by H W Longfellow for class 10
nitinpv4ai
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
iammrhaywood
 
Leveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit InnovationLeveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit Innovation
TechSoup
 
How to Fix [Errno 98] address already in use
How to Fix [Errno 98] address already in useHow to Fix [Errno 98] address already in use
How to Fix [Errno 98] address already in use
Celine George
 
How Barcodes Can Be Leveraged Within Odoo 17
How Barcodes Can Be Leveraged Within Odoo 17How Barcodes Can Be Leveraged Within Odoo 17
How Barcodes Can Be Leveraged Within Odoo 17
Celine George
 
HYPERTENSION - SLIDE SHARE PRESENTATION.
HYPERTENSION - SLIDE SHARE PRESENTATION.HYPERTENSION - SLIDE SHARE PRESENTATION.
HYPERTENSION - SLIDE SHARE PRESENTATION.
deepaannamalai16
 
Wound healing PPT
Wound healing PPTWound healing PPT
Wound healing PPT
Jyoti Chand
 
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
ImMuslim
 
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) CurriculumPhilippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
MJDuyan
 
Bonku-Babus-Friend by Sathyajith Ray (9)
Bonku-Babus-Friend by Sathyajith Ray  (9)Bonku-Babus-Friend by Sathyajith Ray  (9)
Bonku-Babus-Friend by Sathyajith Ray (9)
nitinpv4ai
 
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
Nguyen Thanh Tu Collection
 
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
National Information Standards Organization (NISO)
 
A Visual Guide to 1 Samuel | A Tale of Two Hearts
A Visual Guide to 1 Samuel | A Tale of Two HeartsA Visual Guide to 1 Samuel | A Tale of Two Hearts
A Visual Guide to 1 Samuel | A Tale of Two Hearts
Steve Thomason
 
Educational Technology in the Health Sciences
Educational Technology in the Health SciencesEducational Technology in the Health Sciences
Educational Technology in the Health Sciences
Iris Thiele Isip-Tan
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
deepaannamalai16
 
Temple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation resultsTemple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation results
Krassimira Luka
 

Recently uploaded (20)

Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"
 
CIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdfCIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdf
 
Data Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsxData Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsx
 
How to Predict Vendor Bill Product in Odoo 17
How to Predict Vendor Bill Product in Odoo 17How to Predict Vendor Bill Product in Odoo 17
How to Predict Vendor Bill Product in Odoo 17
 
Haunted Houses by H W Longfellow for class 10
Haunted Houses by H W Longfellow for class 10Haunted Houses by H W Longfellow for class 10
Haunted Houses by H W Longfellow for class 10
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
 
Leveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit InnovationLeveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit Innovation
 
How to Fix [Errno 98] address already in use
How to Fix [Errno 98] address already in useHow to Fix [Errno 98] address already in use
How to Fix [Errno 98] address already in use
 
How Barcodes Can Be Leveraged Within Odoo 17
How Barcodes Can Be Leveraged Within Odoo 17How Barcodes Can Be Leveraged Within Odoo 17
How Barcodes Can Be Leveraged Within Odoo 17
 
HYPERTENSION - SLIDE SHARE PRESENTATION.
HYPERTENSION - SLIDE SHARE PRESENTATION.HYPERTENSION - SLIDE SHARE PRESENTATION.
HYPERTENSION - SLIDE SHARE PRESENTATION.
 
Wound healing PPT
Wound healing PPTWound healing PPT
Wound healing PPT
 
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
 
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) CurriculumPhilippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
Philippine Edukasyong Pantahanan at Pangkabuhayan (EPP) Curriculum
 
Bonku-Babus-Friend by Sathyajith Ray (9)
Bonku-Babus-Friend by Sathyajith Ray  (9)Bonku-Babus-Friend by Sathyajith Ray  (9)
Bonku-Babus-Friend by Sathyajith Ray (9)
 
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
CHUYÊN ĐỀ ÔN TẬP VÀ PHÁT TRIỂN CÂU HỎI TRONG ĐỀ MINH HỌA THI TỐT NGHIỆP THPT ...
 
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
 
A Visual Guide to 1 Samuel | A Tale of Two Hearts
A Visual Guide to 1 Samuel | A Tale of Two HeartsA Visual Guide to 1 Samuel | A Tale of Two Hearts
A Visual Guide to 1 Samuel | A Tale of Two Hearts
 
Educational Technology in the Health Sciences
Educational Technology in the Health SciencesEducational Technology in the Health Sciences
Educational Technology in the Health Sciences
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
 
Temple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation resultsTemple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation results
 

Re ly

  • 1. The New England Journal of Medicine Dabigatran versus Warfarin in Patients with Atrial Fibrillation FEDERICO FAILACH N. M.D. RESIDENTE II AÑO MEDICINA INTERNA UNIVERSIDAD DEL SINÚ .
  • 2. METODO • The Randomized Evaluation of Long-Term Anti- coagulation Therapy (RE-LY) • Patients were recruited from 951 clinical centers in 44 countries. • Blinded fashion, fixed doses of Dabigatran 110 mg or 150 mg twice daily • Unblended fashion, adjusted-dose warfarin. © your company name. All rights reserved. Title of your presentation
  • 3. CRITERIOS DE INCLUSIÓN Y EXCLUSIÓN. • previous stroke or transient • Severe heart-valve disorder ischemic attack. • Stroke with- in 14 days or • Left ventricular ejection severe stroke within 6 months fraction of less than 40% before screening • New York Heart Association • Condition that increased the class II or higher heart-failure risk of hemorrhage symptoms within 6 months • Creatinine clearance of less before screening than 30 ml per minute • Age of at least 75 years or an • Active liver disease, and age of 65 to 74 years pregnancy. • Diabetes mellitus, hypertension, or coronary ar tery disease
  • 4. TABLA 1. © your company name. All rights reserved. Title of your presentation
  • 5. Strategy Film Title © your company name. All rights reserved. Title of your presentation
  • 6. Strategy Make your point. Keep it simple. © your company name. All rights reserved. Title of your presentation
  • 7. Your Decision Which will be your primary focus? © your company name. All rights reserved. Title of your presentation

Editor's Notes

  1. Going into detailEach key point is anchored with a question. I find posing a question to the audience relative to each key point engages them to proactively think and apply the ideas to their own situation vs. just listen to what I have to say.  Slide Notes:Place the title of the first key point where it says “People” and also in the box in the upper right.This may seem redundant, but the repetition is important. The “subline” in the upper right hand box is for a one or two word anchor to the first key point.In my case, the subline for “People” is “Happiness” – it’s the people you surround yourself with in business who impact your happiness.I’ll then carry the “box” in the upper right hand corner, color-coded to that section, to additional content slides in that section.
  2. Short MoviesIn addition to photos, I use several short movie clips in my presentations to demonstrate various skills (showing a team leading a daily huddle) or highlight mini-case studies of growth firms applying our tools and techniques.These videos add credibility to my presentation, letting the audience hear from executives like themselves and how they’ve applied andbenefited from using our tools and techniques. Slide Note:The image on this slide is a picture. Delete the picture for a media placeholder into which you can insert your own movie.
  3. Key PointsFor certain key points, I’ll simply place a few words on a slide without any other visuals,especially when I can’t find an appropriate picture and I want the words to linger in the minds of my audience.Again, I’ll always tell a story that brings the key point alive for the audience while I keep the words on the screen, effectively “burning“ an image in their mind.
  4. Actionable endingI always want to leave the audience with an assignment – some action they need to take.In this case, I’ll ask which of the four decisions do they feel their company needs to focus on the most?Then I’ll give them a few minutes to note their answer and to outline three actions they’ll take when they get back to the office. Slide Notes: If I use photos, I often change the contrast and brightness so that the words stand out. To adjust brightness and contrast for a picture that you set as a slide background, hold down CONTROL, click the slide and then click Format Background. Find brightness and contrast settings on the Adjust Picture tab of that dialog box..To adjust brightness and contrast for a picture on a slide, select the picture and then click the Format Picture tab. Under Adjust, click Corrections to access brightness and contrast options.